Content
All Posts > Content under Healthcare
Biotechnology Stocks - Repligen Major Breakout
Article By:
Taki Tsaklanos
Read
Friday, June 23, 2017 5:10 PM EDT
The biotech index is still way below its all-time highs. However, Repligen managed to climb to its highs, which suggests a sector leader.
In this article: RGEN
Sector Showcase: Biotech Stocks Are The "Transformer" Michael Bay Should Be Watching
Article By:
Matt Weller
Read
Friday, June 23, 2017 2:45 PM EDT
The world's largest biotech fund, the iShares Nasdaq Biotech ETF (IBB), has had a quiet couple of months. For the last four months, the fund has been consolidating in a tight range between about 285.00 and 303.00.
Premarket Biotech Digest – DMPI Receives Approval, PFE Slapped From FDA
Article By:
KKD Healthcare Analytics
Read
Friday, June 23, 2017 9:31 AM EDT
DelMar Pharmaceuticals announced that it has received Institutional Review Board approval to conduct a Phase 3 clinical trial. Pfizer received a setback from the FDA. Roche announced receiving the FDA approval .
The Senate Health Care Bill Has Been Unveiled
Article By:
Marvin R Clark
Read
Friday, June 23, 2017 3:04 AM EDT
The Senate health care bill was unveiled yesterday. The 142-page bill was written entirely behind closed doors and yesterday was the first time the public and most senators have seen the bill.
BIO 2017 International #1: CAR-T Therapies On Solid Tumors
Article By:
Rod Raynovich
Read
Thursday, June 22, 2017 11:45 PM EDT
CAR-T shows great promise against blood cancers but challenges remain for solid tumors. Bellicum Pharmaceuticals, Bluebird bio, Cellectis SA, Juno Therapeutics, Kite Pharma and Poseida Therapeutics are some of the major companies engaged in CAR-T.
Stock Picks: BKD, MDRX, CFX
Article By:
Ryan Mallory
Read
Thursday, June 22, 2017 11:23 PM EDT
Today's stock picks include Brookdale Senior Living, Allscripts and Colfax.
A Market Without A Catalyst On The Other Side Of New Highs
Article By:
Michele Schneider
Read
Thursday, June 22, 2017 9:51 PM EDT
Many states in our country have yet to switch from coal and oil to alternative energy. Our current policies do not support it and countries outside of the US that do, help but only peripherally.
In this article: IBB, AMZN, NFLX, META, GOOGL Also: QQQ, DIA, GDX, GLD, IWM, IYR, IYT, KRE, SMH, SPY, TAN, TLT, USO, UUP, XLU, XRT
3 Biotechnology Stocks To Buy On This Biotechnology Breakout
Article By:
Taki Tsaklanos
Read
Thursday, June 22, 2017 9:11 PM EDT
The biotechnology stock sector is breaking out. After 20 months of consolidation “everyone” forgot about biotechnology stocks, the former leading stock market sector. As it always goes the bull breaks out once all interest is gone.
The 7 Best Discount Retailers: Finding Value & Dividends Among Bargain Stocks
Article By:
SureDividend
Read
Thursday, June 22, 2017 11:01 AM EDT
Internet retail is indeed gaining market share from brick-and-mortar retailers, but plenty of retailers with a physical presence will survive the e-commerce onslaught.
Corbus Moves Lead Candidate To Phase 3 Study, Offers Good Investment Deal
Article By:
KKD Healthcare Analytics
Read
Thursday, June 22, 2017 9:33 AM EDT
Corbus has several catalysts coming up as it progresses with the testing of its lead drug candidate for different indications. Its earliest upcoming catalyst is in the fourth quarter.
In this article: CRBP
Biogen Ready For A Sizable Bounce
Article By:
Bob Lang
Read
Tuesday, June 20, 2017 5:45 PM EDT
The big biopharma company Biogen seems poised for an upside pop soon based on recent turnover and bullish price divergence. It has a good chance to reach the 200 ma for the first time since breaking down in late April.
In this article: BIIB
Becton Dickinson (BDX): A Quality Dividend Aristocrat With Double-Digit Payout Growth
Article By:
Simply Safe Dividends
Read
Tuesday, June 20, 2017 3:10 PM EDT
Becton Dickinson is a high quality healthcare company with a number of long-term growth opportunities. Its acquisitions of CareFusion and C.R. Bard significantly expand its addressable market.
In this article: BDX
Axsome Looks Good On Multiple Catalysts: Fast Track Designation Eases Liquidity Concerns
Article By:
KKD Healthcare Analytics
Read
Tuesday, June 20, 2017 11:27 AM EDT
Axsome Therapeutics Inc. (AXSM) has multiple catalysts coming up in the near future as it has two main drug candidates under Phase 3 testing for multiple conditions. The stock has shown strength as it gained over 12 percent in the past one month.
In this article: AXSM
